BioSight Ltd.   Report issue

For profit Phase 2
Founded: Carmiel Israel (2000)
Status: Acquired by Ayala Pharmaceuticals, Inc, (2023)

Organization Overview

First Clinical Trial
2015
NCT02544438
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BioSight Ltd.

Active Ingredients

Drugs in Phase 2 Trials (3)

Aspacytarabine (3 trials)

cytarabine (cytosar-u) (1 trial)

venetoclax (venclexta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3